Dengue Envelope-1 15kDa
Protein is >95% pure as determined by 10% PAGE (coomassie staining).
Description
Product Specs
Purified by proprietary chromatographic technique.
Product Science Overview
Dengue virus (DV) is a mosquito-borne pathogen belonging to the Flaviviridae family. It is transmitted to humans primarily through the bites of infected Aedes aegypti and Aedes albopictus mosquitoes. Dengue virus is responsible for causing dengue fever, dengue hemorrhagic fever, and dengue shock syndrome, which can be life-threatening. There are four distinct serotypes of dengue virus (DV1, DV2, DV3, and DV4), each capable of causing dengue disease .
The envelope protein (E protein) of dengue virus plays a crucial role in the virus’s ability to infect host cells. It is responsible for binding to host cell receptors and facilitating the fusion and entry of the virus into host cells. The E protein is composed of three domains: Domain I, Domain II, and Domain III (EDIII). Among these, Domain III is particularly important as it stimulates host immune responses by inducing protective and neutralizing antibodies .
Domain III of the E protein is a key target for vaccine development and diagnostic purposes. It contains epitopes that are recognized by neutralizing antibodies, making it a critical component in the design of vaccines aimed at eliciting a strong immune response. The ability of Domain III to induce neutralizing antibodies makes it a promising candidate for the development of dengue vaccines .
The recombinant Dengue Virus Subtype 1 Envelope 15kDa, C-Terminal (Domain III) is a laboratory-produced protein that mimics the natural Domain III of the dengue virus E protein. This recombinant protein is used in research to study the immune response to dengue virus and to develop vaccines and diagnostic tools. By producing the recombinant protein, researchers can investigate its structure, function, and interactions with antibodies without the need for live virus .
The recombinant Domain III protein has shown promise in the development of dengue vaccines. Studies have demonstrated that immunization with recombinant Domain III can induce the production of neutralizing antibodies that protect against dengue virus infection. This approach is particularly valuable because it focuses the immune response on a specific region of the virus that is critical for its ability to infect host cells .
